Corticotropin-releasing factor reduces tumor volume, halts further growth, and enhances the effect of chemotherapy in 4T1 mammary carcinoma in mice

The present study examines the effect of the endogenous neuroendoccrine factor, corticotropin-releasing factor (CRF), alone or in combination with 5-fluorouracil (5-FU), on 4T1 mammary tumor cells in vitro and in vivo. CRF has been detected in breast cancer tissues; however, the biological effects r...

Full description

Saved in:
Bibliographic Details
Published in:Tumor biology 2014-02, Vol.35 (2), p.1365-1370
Main Authors: Stuhr, Linda E. B, Wei, Eddie T., Reed, Rolf K.
Format: Article
Language:English
Subjects:
Angiogenesis
Animals
Apoptosis
Biomedical and Life Sciences
Biomedicine
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Cancer Research
Chemotherapy
Corticotropin-Releasing Hormone - administration & dosage
Female
Fluorouracil - administration & dosage
Hormones
Humans
Mammary Neoplasms, Animal - drug therapy
Mammary Neoplasms, Animal - genetics
Mammary Neoplasms, Animal - pathology
Mice
Neovascularization, Pathologic
Research Article
Rodents
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study examines the effect of the endogenous neuroendoccrine factor, corticotropin-releasing factor (CRF), alone or in combination with 5-fluorouracil (5-FU), on 4T1 mammary tumor cells in vitro and in vivo. CRF has been detected in breast cancer tissues; however, the biological effects reported in the literature are sparse and variable. We found that exogenously administered CRF significantly reduced tumor growth without influencing angiogenesis or cell death. Furthermore, CRF reduced tumor interstitial fluid pressure (P if ) and potentiated the effect of 5-FU. These results show that CRF has antitumor effect on mammary carcinoma in mice.
ISSN:1010-4283
1423-0380
DOI:10.1007/s13277-013-1186-0